One such biomarker, miR-384, exhibits reduced expression in the blood, serum, and CSF of patients with AD, while over-expression of the miRNA is implicated in the suppression of APP and BACE1 expression [102]. This evidence concerns the gene BACE1 and Alzheimer disease.